Literature DB >> 17879201

Macroalbuminuria and microalbuminuria: do both predict renal and cardiovascular events with similar strength?

Paul E de Jong1, Ron T Gansevoort, Stephan J L Bakker.   

Abstract

Until recently, most attention given to patients with macroalbuminuria has focused on their worse renal prognosis, while in contrast, patients with microalbuminuria were mostly considered to be at increased cardiovascular risk. In recent years, however, evidence has been accumulating that this distinction between the 2 -- either large or small quantities of albumin in the urine -- is not that clear. On the one hand, various studies have reported that macroalbuminuria also bears an increased cardiovascular risk. Interestingly, the extent to which albumin loss can be reduced in patients with macroalbuminuria is associated not only with a better renal prognosis, but also similarly with a better cardiovascular prognosis. On the other hand, patients with microalbuminuria not only have an impaired cardiovascular, but also an impaired renal, prognosis. These latter findings in microalbuminuria are especially of importance for the renal community, as screening for albuminuria is not carried out systematically even in patients with increased risk for microalbuminuria, such as those with diabetes and those with essential hypertension. When promoting routine screening for albuminuria, one should realize, moreover, that such projects will most likely be much more cost-effective when directed to preventing not only renal end points, but also CV end points.

Entities:  

Mesh:

Year:  2007        PMID: 17879201

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  12 in total

1.  Apolipoprotein B attenuates albuminuria-associated cardiovascular disease in prevention of renal and vascular endstage disease (PREVEND) participants.

Authors:  James P Corsetti; Ron T Gansevoort; Stephan J L Bakker; Charles E Sparks; Priya Vart; Robin P F Dullaart
Journal:  J Am Soc Nephrol       Date:  2014-05-22       Impact factor: 10.121

2.  Microvascular Disease, Peripheral Artery Disease, and Amputation.

Authors:  Joshua A Beckman; Meredith S Duncan; Scott M Damrauer; Quinn S Wells; Joey V Barnett; David H Wasserman; Roger J Bedimo; Adeel A Butt; Vincent C Marconi; Jason J Sico; Hilary A Tindle; Marc P Bonaca; Aaron W Aday; Matthew S Freiberg
Journal:  Circulation       Date:  2019-07-08       Impact factor: 29.690

3.  Assessment of the relationship between 25-hydroxyvitamin D and albuminuria in type 2 diabetes mellitus.

Authors:  Seyed Alireza Zomorodian; Maryam Shafiee; Zeinab Karimi; Fatemeh Masjedi; Amirhossein Roshanshad
Journal:  BMC Endocr Disord       Date:  2022-07-04       Impact factor: 3.263

4.  High variability of albuminuria in nondiabetic population: the Takahata Study.

Authors:  Kazuko Suzuki; Tsuneo Konta; Satoshi Takasaki; Ami Ikeda; Kazunobu Ichikawa; Hitoshi Sato; Yoko Shibata; Tetsu Watanabe; Takeo Kato; Sumio Kawata; Isao Kubota
Journal:  Clin Exp Nephrol       Date:  2009-05-20       Impact factor: 2.801

Review 5.  Identification and management of albuminuria in the primary care setting.

Authors:  Louis Kuritzky; Robert Toto; Peter Van Buren
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-02-01       Impact factor: 3.738

6.  Test characteristics of urine dipstick for identifying renal insufficiency in patients with diabetes.

Authors:  Sanjay Arora; Theodore Long; Michael Menchine
Journal:  West J Emerg Med       Date:  2011-05

7.  Understanding the mechanisms of proteinuria: therapeutic implications.

Authors:  Jorge E Toblli; P Bevione; F Di Gennaro; L Madalena; G Cao; M Angerosa
Journal:  Int J Nephrol       Date:  2012-07-04

Review 8.  Proteinuria and its relation to cardiovascular disease.

Authors:  Gemma Currie; Christian Delles
Journal:  Int J Nephrol Renovasc Dis       Date:  2013-12-21

9.  Urinary alpha-1 antitrypsin and CD59 glycoprotein predict albuminuria development in hypertensive patients under chronic renin-angiotensin system suppression.

Authors:  Laura Gonzalez-Calero; Marta Martin-Lorenzo; Fernando de la Cuesta; Aroa S Maroto; Montserrat Baldan-Martin; Gema Ruiz-Hurtado; Helena Pulido-Olmo; Julian Segura; Maria G Barderas; Luis M Ruilope; Fernando Vivanco; Gloria Alvarez-Llamas
Journal:  Cardiovasc Diabetol       Date:  2016-01-16       Impact factor: 9.951

10.  Short-Term High-Dose Vitamin E to Prevent Contrast Medium-Induced Acute Kidney Injury in Patients With Chronic Kidney Disease Undergoing Elective Coronary Angiography: A Randomized Placebo-Controlled Trial.

Authors:  Yousef Rezaei; Kamal Khademvatani; Behzad Rahimi; Mehran Khoshfetrat; Nasim Arjmand; Mir-Hossein Seyyed-Mohammadzad
Journal:  J Am Heart Assoc       Date:  2016-03-15       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.